House of Lords

Business

Northland Cuts Bitdeer Price Target to $25 After December Update, Maintains Bullish Stance

Northland Capital has revised its price target for Bitdeer Technologies (BTDR) downward to $25, citing a more conservative valuation approach following the company's latest operational update. The firm, however, reaffirmed its Outperform rating, signaling continued confidence in the blockchain and high-performance computing firm's long-term strategy.

Jan 30, 2026

Business

Analysts Bullish on Ovid Therapeutics as Pipeline Progresses, Penny Stock Gains Attention

Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.

Jan 30, 2026

Business

Century Therapeutics Gains Analyst Confidence with Extended Cash Runway and Key IND Submission on Horizon

Piper Sandler raises its price target for Century Therapeutics (IPSC), highlighting the biotech firm's robust financial position extending into 2029 and an upcoming Investigational New Drug application for its lead cell therapy candidate, CNTY-813.

Jan 30, 2026

Business

Citi Boosts Lexicon Pharmaceuticals Outlook on Novo Nordisk Partnership Progress

Citi raises Lexicon Pharmaceuticals' price target to $2.10, citing strong momentum from its collaboration with Novo Nordisk on obesity drug candidate LX9851 and improved financials.

Jan 30, 2026

Business

Fiserv's Plunge: A Value Trap or a Turnaround Bet for 2026?

Once a fintech stalwart, Fiserv shares have cratered 70% in a year. As its 'One Fiserv' restructuring plan kicks in, investors are grappling with whether the beaten-down stock is a bargain or a warning sign.

Jan 30, 2026

Business

Beyond the Roth Hype: Why Traditional Retirement Accounts May Be the Smarter Tax Move for Many

While Roth accounts dominate the retirement planning conversation, a closer look at current tax laws and long-term income strategies reveals a compelling case for prioritizing pre-tax contributions. We examine the data with an expert and explore what gold's historical returns tell us about diversification.

Jan 30, 2026

Business

Standex Delivers Strong Q2 Growth, Fueled by Grid and New Products; Reiterates FY2026 Outlook

Standex International reports robust second-quarter results, with organic growth reaching 6.4% and record quarterly orders. The company's strategic pivot towards high-growth markets like electrical grid infrastructure and new product development is now materially boosting the top line.

Jan 30, 2026

Business

Bunge Shares Surge to Three-Year Peak as Agribusiness Giant Rides Market Momentum

Global agribusiness leader Bunge Ltd. (BG) reached a fresh three-year high this week, buoyed by strong technical indicators and sustained momentum in the essential food supply chain sector, even as analyst price targets remain widely dispersed.

Jan 30, 2026

Business

Walker & Dunlop's Slide: Three Red Flags for Investors and a Safer Alternative

While the S&P 500 has climbed, Walker & Dunlop shares have tumbled over 14% in six months. We analyze the underlying weaknesses in its financials and highlight a more compelling opportunity for value-focused portfolios.

Jan 30, 2026

Business

Analysts Sound Caution on ICF International as Backlog Shrinks, Point to Alternative Tech Play

While ICF International's stock has kept pace with the broader market, analysts highlight concerns over declining backlog and slowing revenue growth, suggesting investors may find better opportunities elsewhere.

Jan 30, 2026

Business

Therapeutics Sector Shows Resilience in Q3: United Therapeutics Lags as Halozyme and Biogen Outperform

A mixed third-quarter earnings season for therapeutics stocks reveals divergent paths, with United Therapeutics missing estimates while peers like Halozyme and Biogen post strong beats. Sector-wide revenue growth and positive stock reactions suggest underlying investor confidence despite regulatory and pricing headwinds.

Jan 30, 2026

World

ISIL Claims Responsibility for Niger Airport Assault as Military Ruler Accuses Regional Powers

The Islamic State group has claimed a coordinated attack on a key airbase near Niamey's international airport, amid escalating tensions after Niger's junta leader pointed fingers at France, Benin, and Ivory Coast.

Jan 30, 2026

World

Exclusive: U.S. Nears Deal to Deport Migrants to Argentina, Bolstering Trump's Immigration Agenda

The United States and Argentina are in final-stage negotiations on an agreement that would see the U.S. deport migrants from third countries to the South American nation, according to a New York Times report. The potential deal aligns with the Trump administration's push to expand removal destinations and marks a sharp shift in Argentina's historically open immigration policy under President Javier Milei.

Jan 30, 2026

Business

U.S. Drilling Activity Stalls Amid Mixed Signals for Oil and Gas

The U.S. rig count saw a marginal increase this week, yet remains significantly below last year's levels as crude production dips and completions activity sends conflicting signals.

Jan 30, 2026

Business

Lazard Beats Estimates on Strong Advisory, Asset Management Performance

Financial services firm Lazard (LAZ) reported better-than-expected fourth-quarter results, driven by record advisory fees and robust asset growth, signaling resilience in a challenging market.

Jan 30, 2026

Business

Wall Street's Bold Bets: One Stock Poised to Shine, Two Facing Headwinds

Analysts have pinned high hopes on several names, but a closer look reveals a more nuanced picture. We examine one company likely to justify the optimism and two where significant risks may be overshadowing the bullish price targets.

Jan 30, 2026

Business

KeyBanc Upgrades LivaNova to Overweight, Sees 27% Upside as MedTech Valuations Normalize

KeyBanc Capital Markets has upgraded LivaNova PLC (LIVN) from Sector Weight to Overweight, setting an $81 price target. The move reflects a broader positive shift in analyst sentiment towards the medical technology sector as valuation premiums ease.

Jan 30, 2026

Business

iRhythm Holdings Gains Wall Street Favor as Cardiac Monitoring Demand Surges

Morgan Stanley and Evercore ISI reaffirm bullish ratings on iRhythm, citing strong Q4 preliminary results and growth potential from its next-gen cardiac monitoring technology.

Jan 30, 2026

Business

Guggenheim Boosts Bruker Price Target to $58, Citing Strong Diagnostics Outlook

Guggenheim analyst Subbu Nambi raises her price target on Bruker Corporation (BRKR) from $53 to $58, maintaining a Buy rating and projecting nearly 25% upside, as the life sciences tools sector shows resilience.

Jan 30, 2026

Business

Hedge Funds Bet Big on Insulet's Omnipod: Analysts See Over 40% Upside for Diabetes Tech Leader

Insulet Corp (PODD) has emerged as a top pick among hedge funds in the medical device sector, buoyed by overwhelmingly bullish analyst ratings and a price target suggesting significant growth potential. The company's innovative tubeless insulin pump system is seen as a key driver.

Jan 30, 2026